Nintedanib esylate is the active salt form of nintedanib delivered in soft gelatin capsules, most widely known under the brand Ofev. It is unusual among targeted agents in that regulators have approved it across several unrelated fibrotic and oncologic indications, each supported by separate clinical evidence. For buyers and registrants, the regulatory footprint and the manufacturing quality standards are as relevant as the clinical profile. This article outlines the approval landscape and the quality framework behind the product.
Health authorities including the FDA, EMA and NMPA have authorized nintedanib for idiopathic pulmonary fibrosis, for systemic sclerosis-associated interstitial lung disease, and for other chronic fibrosing interstitial lung diseases with a progressive phenotype. In oncology it is approved, in combination with docetaxel, for previously treated advanced NSCLC of adenocarcinoma histology. Generic versions have also been authorized in multiple regions, referencing the original medicine. Each indication rests on distinct trial data, so a marketing authorization in one indication does not automatically cover another, a point that matters for market access and labeling. The medicine is taken twice daily with food, and dose reduction is permitted when tolerability requires it, details that sit within each regional label rather than the shared mechanism.
As a prescription kinase inhibitor, nintedanib esylate is manufactured under current Good Manufacturing Practice, with finished-product testing for identity, potency, content uniformity and impurities. The soft-capsule form requires controlled filling and sealing to protect the suspension and maintain stability at room temperature. Stability data support storage below 25 degrees C in the original package, protected from moisture. Importers should confirm a valid marketing authorization, a current Certificate of Pharmaceutical Product where required, and GMP evidence from the manufacturing site. These documents form the backbone of regulatory defensibility in cross-border pharmaceutical trade. Finished capsules are also subject to dissolution and impurity-profile testing so that release specifications stay aligned with the registered dossier across manufacturing sites.
Q: In which indications is nintedanib approved? A: Major approvals cover idiopathic pulmonary fibrosis, systemic sclerosis-associated ILD, progressive fibrosing ILD, and previously treated advanced NSCLC (adenocarcinoma) with docetaxel.
Q: Is nintedanib esylate the same molecule as Ofev? A: Yes. Ofev is the established brand; nintedanib esylate is the salt form of the same active substance supplied in soft capsules.
Q: What quality documents support import of nintedanib? A: A valid marketing authorization, a CPP where required, GMP certification of the site, and per-lot release testing (CoA) are the typical backbone for compliant import.
Nintedanib esylate is the active salt form of nintedanib delivered in soft gelatin capsules, most widely known under the brand Ofev. It is unusual among targeted agents in that regulators have approved it across several unrelated fibrotic and oncologic indications, each supported by separate clinical evidence. For buyers and registrants, the regulatory footprint and the manufacturing quality standards are as relevant as the clinical profile. This article outlines the approval landscape and the quality framework behind the product.
Health authorities including the FDA, EMA and NMPA have authorized nintedanib for idiopathic pulmonary fibrosis, for systemic sclerosis-associated interstitial lung disease, and for other chronic fibrosing interstitial lung diseases with a progressive phenotype. In oncology it is approved, in combination with docetaxel, for previously treated advanced NSCLC of adenocarcinoma histology. Generic versions have also been authorized in multiple regions, referencing the original medicine. Each indication rests on distinct trial data, so a marketing authorization in one indication does not automatically cover another, a point that matters for market access and labeling. The medicine is taken twice daily with food, and dose reduction is permitted when tolerability requires it, details that sit within each regional label rather than the shared mechanism.
As a prescription kinase inhibitor, nintedanib esylate is manufactured under current Good Manufacturing Practice, with finished-product testing for identity, potency, content uniformity and impurities. The soft-capsule form requires controlled filling and sealing to protect the suspension and maintain stability at room temperature. Stability data support storage below 25 degrees C in the original package, protected from moisture. Importers should confirm a valid marketing authorization, a current Certificate of Pharmaceutical Product where required, and GMP evidence from the manufacturing site. These documents form the backbone of regulatory defensibility in cross-border pharmaceutical trade. Finished capsules are also subject to dissolution and impurity-profile testing so that release specifications stay aligned with the registered dossier across manufacturing sites.
Q: In which indications is nintedanib approved? A: Major approvals cover idiopathic pulmonary fibrosis, systemic sclerosis-associated ILD, progressive fibrosing ILD, and previously treated advanced NSCLC (adenocarcinoma) with docetaxel.
Q: Is nintedanib esylate the same molecule as Ofev? A: Yes. Ofev is the established brand; nintedanib esylate is the salt form of the same active substance supplied in soft capsules.
Q: What quality documents support import of nintedanib? A: A valid marketing authorization, a CPP where required, GMP certification of the site, and per-lot release testing (CoA) are the typical backbone for compliant import.
english
français
Deutsch
Italiano
Русский
Español
português
Nederlandse
ελληνικά
日本語
한국
العربية
हिन्दी
Türkçe
indonesia
tiếng Việt
ไทย
বাংলা
فارسی
polski
